Canaccord raised the firm’s price target on AxoGen (AXGN) to $22 from $18 and keeps a Buy rating on the shares. The firm updated its model following the preannouncement of its Q4 results. The shares are now afforded a premium versus the small cap comp group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
Questions or Comments about the article? Write to editor@tipranks.com